SCHEMBL690926

SCHEMBL690926

Cn1ccc2cccc(C=O)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.41
TRIM24 O15164 2/20 0.39
TRIM33 Q9UPN9 2/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 2/20 0.38
IMPDH2 P12268 1/20 0.38
TSHR P16473 1/20 0.38
RASGRP1 O95267 1/20 0.35
PRKCA P17252 1/20 0.35
PRKCE Q02156 1/20 0.35
RASGRP3 Q8IV61 1/20 0.35
ERN1 O75460 3/20 0.35
CMA1 P23946 1/20 0.35
TLR2 O60603 1/20 0.34
TLR1 Q15399 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29935861 1.00 CYP2A6 (0.41) CYP2A6TRIM24TRIM33MEN1LMNA
SCHEMBL18029054 0.81 ALDH1A1 (0.33) CYP2A6ALDH1A1RASGRP1PRKCAPRKCE
SCHEMBL27906608 0.77 LMNA (0.39) CYP2A6TRIM24TRIM33MEN1LMNA
SCHEMBL28045310 0.77 MEN1 (0.39) CYP2A6TRIM24TRIM33MEN1LMNA
SCHEMBL27955988 0.77 MEN1 (0.39) CYP2A6TRIM24TRIM33MEN1LMNA
SCHEMBL10416002 0.76 CA1 (0.45) LMNAALDH1A1CMA1CA1CA2
SCHEMBL10416005 0.76 CA1 (0.45) LMNAALDH1A1CMA1CA1CA2
SCHEMBL2054120 0.75 APP (0.36) TDP1ALDH1A1ERN1TLR2TLR1
SCHEMBL30430847 0.74 CYP2A6 (0.39) CYP2A6TRIM24TRIM33MEN1KMT2A
SCHEMBL2312217 0.73 CYP2A6 (0.41) CYP2A6TRIM24TRIM33ALDH1A1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 CN disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 EP disclosed
WO-2024196850-A1 DEVELOPMENT OF HIGHLY FLUOROGENIC STYRENE PROBES FOR VISUALIZING RNA IN LIVE CELLS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-09-26 WO disclosed
EP-3990442-B1 RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION INC (US) 2024-02-28 EP disclosed
WO-2023201012-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-10-19 WO disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 WO disclosed
CN-112608320-B Piperidine compound and preparation method and medical application thereof 中国药科大学 2023-03-17 CN disclosed
US-20220388998-A1 RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. 2022-12-08 US disclosed
WO-2021143792-A1 PIPERIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国药科大学 2021-07-22 WO disclosed
WO-2005058834-A2 QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE WYETH (US) 2005-06-30 WO disclosed
US-20050131014-A1 Quinolines useful in treating cardiovascular disease WYETH (US) 2005-06-16 US disclosed
WO-2004082586-A2 PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS AFFINIUM PHARMACEUTICALS, INC. (US) 2004-09-30 WO disclosed
WO-2004052890-A1 HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY AFFINIUM PHARMACEUTICALS, INC. (CA) 2004-06-24 WO disclosed
EP-1325011-B1 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES LILLY CO ELI (US) 2004-05-06 EP disclosed
US-20040048915-A1 Methods and compounds for treating proliferative diseases ENGLER THOMAS ALBERT (US) 2004-03-11 US disclosed
EP-1325011-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2003-07-09 EP disclosed
WO-2002028861-A2 METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2002-04-11 WO disclosed
CN-1067988-C Indoloylguanidine derivatives SUMITOMO PHARMACEUTICS K K (JP) 2001-07-04 CN disclosed
US-4948796-A TREATING CEREBO-VASCULARE DISEASES TOYAMA CHEMICAL CO., LTD. (JP) 1990-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048915-A1 Methods and compounds for treating proliferative diseases CDK4, CCNI, CCNA1 CYP2A6 3148/4885TRIM24 3074/4885TRIM33 3399/4885
US-20220388998-A1 RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF ROCK1, ROCK2, RHOA CYP2A6 4791/4885TRIM24 3029/4885TRIM33 3728/4885
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 CYP2A6 524/4885TRIM24 357/4885TRIM33 272/4885
US-20050131014-A1 Quinolines useful in treating cardiovascular disease NR1H2, NR1H3, SREBF1 CYP2A6 386/4885TRIM24 1957/4885TRIM33 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.